Dysregulated BH4 metabolism facilitates immunosuppression in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive, malignant, and lethal cancers, displaying strong resistance to immunotherapy. In this issue of Cell Metabolism, a study by Liu et al. identifies tetrahydrobiopterin metabolic dysregulation as a key driver for the immunosuppressive PDAC environment in mouse and human. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive, malignant, and lethal cancers, displaying strong resistance to immunotherapy. In this issue of Cell Metabolism, a study by Liu et al. identifies tetrahydrobiopterin metabolic dysregulation as a key driver for the immunosuppressive PDAC environment in mouse and human. QDPR deficiency drives immune suppression in pancreatic cancerLiu et al.Cell MetabolismApril 19, 2024In BriefThe critical roles and mechanisms of biopterin metabolism in resistance to immune checkpoint blockade (ICB) therapy remain unknown. Liu et al. demonstrate the interplay between tumor-cell-hijacked biopterin metabolism and tumor immunity in PDAC and propose that QDPR deficiency causes ICB resistance in PDAC. Full-Text PDF